[Economic impact of management strategies for streptococcal B cervico-vaginal infections during pregnancy].
Chaix
C
C
Santé publique, Fédération HITEQ, Hôpital Henri-Mondor, Créteil.
Durand-Zaleski
I
I
D000900:Anti-Bacterial Agents / Q000191:economics; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D005260:Female; D017048:Health Care Costs; D006801:Humans; D008403:Mass Screening / Q000191:economics; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000191:economics* / Q000517:prevention & control; D011256:Pregnancy Outcome; D013290:Streptococcal Infections / Q000191:economics* / Q000517:prevention & control; D013292:Streptococcus agalactiae; D002577:Uterine Cervical Diseases / Q000191:economics* / Q000517:prevention & control; D014623:Vaginal Diseases / Q000191:economics* / Q000517:prevention & control
D000900:Anti-Bacterial Agents
Impact économique des stratégies de prise en charge des infections cervico-vaginales à streptocoque B pendant la grossesse.